US Psoriatic Arthritis Treatment Market Size Likely to Grow at a CAGR of 9.87% By 2034

Market Size and Growth

As per the US Psoriatic Arthritis Treatment Market size analysis conducted by the CMI team, the US psoriatic arthritis treatment market is expected to record a CAGR of 9.87% from 2025 to 2034. In 2025, the market size was USD 4.1 Billion. By 2034, the valuation is anticipated to reach USD 9.31 Billion.

Overview

As per the industry experts at CMI, the U.S. psoriatic arthritis treatment market is likely to witness a notable CAGR during the forecast period. This could be attributed to the growing prevalence of PsA and disorders associated with it all across the U.S. A robust pipeline of new biosimilars and drugs, especially biologics and targeted therapies such as TYK2 and JAK inhibitors, is driving the growth. The injectable form of biologics dominates owing to the parenteral route of administration, thereby offering a higher level of effectiveness.

Key Trends & Drivers

• Pharmacies to Determine Growth: Hospitals are amongst the major channels owing to the requirement of systemic therapies along with the need for managing critical conditions, supported by centralized inventory and healthcare providers. Online pharmacy sector is expected to witness the highest growth, driven by increasing use of the internet, convenience pertaining to home delivery, and expansion of telehealth services.

• Advancements in Biologic Therapies to Catalyze the Market: Effectiveness provided by advanced biologic drugs is targeting specified inflammatory pathways for reducing symptoms and slowing disease progression. Research states that the year 2024 witnessed the dominance of biologics, accounting for almost 50% of the overall revenue generated. Some of the recently approved therapies include BIMZELX (bimekizumab), Sotyktu (deucravacitinib), and IV Cosentyx (secukinumab).

Report Scope

SWOT Analysis

• Strengths: The Majority of players are handsomely investing in R&D activities related to clinical trials and developing new drugs. Also, speedy approvals from the U.S. FDA are amongst the strengths of the U.S. psoriatic arthritis treatment market. Plus, the rise in understanding of disease with the rise in rates of diagnosis with widespread adoption of the medical therapies is expediting the market.

• Weaknesses: As of now, there is no definite cure for psoriatic arthritis. In other words, all the treatments are focusing on the management of symptoms and slowing the progression of disease. Also, management of PsA’s varied aspects is likely to need multi-faceted and complex treatment plans. The new entrants may also think twice before entering the market due to higher initial costs.

• Opportunities: Launching of new biologics coupled with higher availability of biosimilars is likely to offer better options of treatment. Also, continual focus on early intervention and diagnosis can noticeably enhance long-term outcomes and adherence to treatment. Plus, it has been reported that there are still many unmet clinical needs, particularly for treatments that could address every aspect of the disease in a comprehensive manner. Development of biosimilar psoriatic arthritis drugs is on the anvil.

• Threats: Development of cost-effective, non-biologic treatments is likely to pose a threat to the market structure that exists. Also, economic downturns/alterations with respect to insurance policies are likely to limit access to the high-cost therapies. It has also been observed that certain treatments’ long-term use could cause side effects, thereby posing potential risk for patients.

List of the prominent players in the US Psoriatic Arthritis Treatment Market:

• Novartis
• Bristol-Myers Squibb
• AbbVie
• Pfizer
• Johnson & Johnson Services Inc.
• Amgen Inc.
• Eli Lilly and Company
• Others

The US Psoriatic Arthritis Treatment Market is segmented as follows:

By Drug Class

• NSAIDs
• DMARD
• Biologics

By Type

• Prescriptions
• OTC

By Route of Administration

• Topical
• Oral
• Injectable